Resistance to ET (i.e., to either aromatase inhibitors or Tam) arises in about 50% of women with luminal BC and leads to disease relapse through the formation of metastasis to secondary sites (e.g., lung, bone, brain, and liver). The gene discussed is CYP19A1; the disease is breast cancer.